Clinical Trial

A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the effects of the addition of SG301 injection to pomalidomide and dexamethasone in subjects with relapsed or refractory multiple myeloma.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-07-17; most recent amendment 2026-07-09.
Trial Details
NCT Number NCT06508983
Lead Sponsor Hangzhou Sumgen Biotech Co., Ltd.
Conditions Relapsed/Refractory Multiple Myeloma
Enrollment 360 participants
Start Date 2024-06-14
Primary Completion 2027-03-31 (estimated)
Study Completion 2028-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-10